Mutations in pannexin genes linked to degenerative changes in erosive hand osteoarthritis families

What is it about?

Erosive hand osteoarthritis (EHOA) is a severe form of joint disease that causes pain, inflammation, and breakdown of cartilage and bone in the hands. In this study, we investigated families in which EHOA was inherited across generations to better understand its genetic causes. We identified mutations in two genes, PANX1 and PANX3, that affect how cells communicate through channel proteins. Altering the activity of these channel proteins would disrupt cellular communication and, in turn, impact joint health. Although these mutations altered channel function in opposite ways, with the PANX1 gene mutation causing hyperactivity and the PANX3 gene mutation causing a loss of channel function, both ultimately led to cellular damage and degeneration.

Featured Image

Photo by Towfiqu barbhuiya on Unsplash

Photo by Towfiqu barbhuiya on Unsplash

Why is it important?

Erosive Hand Osteoarthritis (EHOA) is a severe and currently untreatable joint disease that leads to progressive inflammation and destruction of cartilage and bone in the hands, yet its underlying causes remain poorly understood. By studying families with inherited forms of the disease, we identified mutations in the pannexin channel genes PANX1 gene and PANX3 gene, revealing a previously unrecognized genetic contribution to disease development. Notably, this study reports the first-ever disease-associated mutation in PANX3. Importantly, this work connects patient genetic screening directly to functional biology, moving from inherited mutations in families to pinpointing how these changes alter the protein channel and cell health in the lab. Together, these findings are the first to link pannexins to joint degeneration in EHOA, providing a new mechanistic framework for understanding disease onset. Beyond advancing fundamental insight into osteoarthritis biology, this work opens the door to exploring pannexins as potential targets for future disease-modifying therapies in a condition that currently lacks any effective treatment options.